Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use

Article Article scientifique Article Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use eng 2018-10-30 2018-12 author Noirot Camille Maëlle 934082 author Mainta Ismini Charis 869258 Département de radiologie et informatique médicale (RADIO) author Mendes Aguiar Santos Aline 847282 dept de réadaptation et gériatrie (MIGRG) author Andryszak Paulina 842585 author Visvaratnam Hishayine 803750 author Unschuld Paul 951221 Département de psychiatrie (PSYAT) author Frisoni Giovanni 810190 dept de réadaptation et gériatrie (MIGRG) author Garibotto Valentina 0000-0003-2422-698X 704817 Département de radiologie et informatique médicale (RADIO) 471-482 10.1007/s40336-018-0297-4 2281-5872 http://link.springer.com/10.1007/s40336-018-0297-4 Purpose : The development and validation of molecular imaging markers for the neuropathological hallmarks of neurodegenerative diseases associated with cognitive impairment is a reality since two decades. Amyloid PET tracers have been validated analytically and are currently tested for their clinical utility. More recently tracers targeting specifically tau deposits have been developed and are currently tested in large clinical studies. The availability of these markers opens the possibility for precision medicine in a field that was limited by a gold standard diagnosis occurring only postmortem. Aim of this review is to summarize the main findings obtained using tau-specific PET tracers in clinical cohorts of patients with cognitive impairment. Methods and Results : We report the results of a systematic literature review. Various approaches for automated image assessment have been tested, while visual rating strategies have not been validated yet. In the AD spectrum an increase in cortical binding has been consistently observed, with a topography correlated with the profile of cognitive impairment and in agreement with the knowledge on tau pathology from neuropathological series. The evidence in non-AD diseases is more limited, with discordant findings in different cohorts and with different tracers. Conclusion : Post-mortem validations of in vivo data in large cohorts and studies investigating the clinical added value of this biomarker in comparison with others will be required before routine clinical use of this new modality. Tau Positron emission tomography (PET) Alzheimer’s disease (AD) Biomarker Tauopathy Dewey 616.0757 Dewey 618.97 Velux Stiftung 1123 Swiss National Science Foundation The Biological Basis of Cognitive Impairment due to Suspected Non-Alzheimer’s Pathology (SNAP) : Studying the interplay between amyloidosis and tau-related neurodegeneration 169876 CH European Commission Common mechanisms and pathways in Stroke and Alzheimer's disease. 667375 CoSTREAM EU H2020 62 Département de radiologie et informatique médicale 227 65 Département de réadaptation et gériatrie 22B false 1389 Santé mentale gériatrique et médecine de précision 1041 1222 Laboratoire de neuroimagerie et de traceurs moléculaires innovants 984 853 Troubles de mémoire et maladie d'Alzeimer 935 Clinical and Translational Imaging 6 6 7652166d-debc-426f-8a33-12a19859f23c Article (Published version) Restricted Article_scientifique_from_crossref.pdf 1420027 application/pdf 18703aa6896083288e0eb15a4854dfb2fb47f674c474b1cf6601b2bbd409c87b restrictedAccess Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie

Title	Published in	Year	Views	Downloads

[⁶⁸Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review	American journal of nuclear medicine and molecular imaging	2020	206	231
Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use	Clinical and Translational Imaging	2018	4	0

Archive ouverte UNIGE

Noirot, Camille Maëlle